
What smart money is saying about Sartorius Stedim Biotech S.A.
1 fund in our archive has pitched Sartorius Stedim Biotech S.A. — most recently Baron Health Care Fund in June 2026.
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
Get an email when a fund writes about it
Position history
Every position in Sartorius Stedim Biotech S.A. on record in the archive was reported in Q2 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 1 | 0 | 1 |
Fund activity · 1 position · 1 move
- New positionBaron Health Care FundJune 2026
“We established a new position in Sartorius Stedim Biotech S.A. , which supplies equipment and reagents to biopharmaceutical companies for the production of biologic drugs.”
Read the letterSartorius Stedim Biotech S.A.
Fund coverage · 1 thesis
- Baron Health Care FundJune 2026
Sartorius Stedim Biotech supplies single-use bioprocessing equipment, benefiting from industry growth, customer advantages, and valuation upside.
Read the full thesis
Read every full thesis on Sartorius Stedim Biotech S.A.
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→